Treatment of adult inflammatory myositis with rituximab: An emerging therapy for refractory patients

Journal of Clinical Rheumatology

Volumn 15, Issue 7, 2009, Pages 338-340

  Majmudar, Shefali ^a   Hall, Harald A ^a   Zimmermann, Bernard ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

Anti B cell therapy; Inflammatory myopathy; Myositis; Rituximab

Indexed keywords

AZATHIOPRINE; CREATINE KINASE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID;

ADULT; ARTICLE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ACTIVITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MUSCLE BIOPSY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOSITIS; POLYMYOSITIS; PRIORITY JOURNAL; PUNCH BIOPSY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOCYTE DEPLETION; MUSCLE STRENGTH; MYOSITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70350166145     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181bb8e70     Document Type: Article

References (15)

1. Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28:2230-2237.
2. Oddis CV. Idiopathic inflammatory myopathies: a treatment update. Curr Rheumatol Rep. 2003;5:431-436.
3. Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 1998;41:392-399.
4. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology. 2007;69:2008-2019.
5. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B-cell therapy. Arthritis Rheum. 2003;48:1484-1492.
6. Kneitz C, Wilhelm M, Tony HP. Effective B-cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology. 2002;206:519-527.
7. Di Martino SJ, Kagen LJ. Newer therapeutic approaches: inflammatory muscle disorders. Rheum Dis Clin North Am. 2006;32:121-128.
8. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601-607.
9. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open label prospective study. J Rheumatol. 2007;34:1864-1868.
10. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913-920.
11. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol. 2006;33:1021-1026.
12. Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord. 2006;16:334-336.
13. Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol. 2005;11:264-266.
14. Lambotte O, Kotb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol. 2005;32:1369-1370.
15. Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis. 2006;65:974-975.